Abstract Details

Title HLA genotype as a marker of Multiple Sclerosis prognosis: results from a multicentric extension study

Topic Multiple Sclerosis

Presentation(s) P5 - Poster Session 5 (5:30 PM-6:30 PM)

Poster/Presentation
Number 15-008

Objective To increase evidence of possible association of HLA genotype with disease status and progression in MS based on sensitive and complex clinical and MRI parameters.

Background In a previous monocentric study, we investigated the relation between HLA and MS disease progression over 2 years showing better outcome in HLA-A*02 and worse outcome for HLA-B*07 and HLA-B*44 carriers.

Design/Methods 146 MS patients underwent HLA typing. Patient MS status was assessed at 3 timepoints in a 4-year interval, based on clinical scores (EDSS, MSSS, T25FW, 9-HPT, SDMT, BVMT, CVLT-II) and evaluation of magnetic resonance imaging (MRI). Quantitative brain MRI values were obtained for whole brain atrophy, FLAIR lesion volume change and number of new lesions using MSmetrix. Predefined HLA patient groups were compared as of disease status and progression. To obtain an overall impression of protectiveness of a certain HLA alleles across biomarkers, the weighted average of test statistics from the individual ANOVA was considered. HLA groups were compared in terms of progression of clinical or MRI variables using the two-sided Fisher’s exact test. The effect of multiple covariates, including age, gender, disease duration and scan parameters, was also evaluated using a regression analysis.

Results

HLA-B*08 allele was associated with smaller whole brain volume and HLA-B*44 with higher number of new FLAIR lesions. The absence of HLA-DRB1*15 in presence of HLA-A*02 amplified the positive effect of the latter on MS. HLA-B*07 showed a global negative effect on disease progression.

Conclusions This larger study with a longer follow up confirmed what we have shown previously. HLA-A*02 allele is associated with better MS outcomes and HLA-B*08, HLA-B*44 and HLA-B*07 have a potential negative effect. The amount of effect of HLA-A*02 depends on presence of HLA-DRB1*15.

Authors/Disclosures
Andreas Lysandropoulos (Parexel) PRESENTER	Andreas Lysandropoulos has nothing to disclose.
Gaetano Perrotta, MD (Hopital Erasme)	No disclosure on file
	No disclosure on file
Annemie Ribbens	Annemie Ribbens has received personal compensation for serving as an employee of icometrix. Annemie Ribbens has stock in icometrix. Annemie Ribbens has received intellectual property interests from a discovery or technology relating to health care.
Pietro Maggi, MD, PhD (CHUV Service de neurologie)	No disclosure on file
Marie Theaudin, MD (Centre Hospitalier)	No disclosure on file

��ɫ��

��ɫ��